Detalles de la búsqueda
1.
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.
Euro Surveill
; 29(13)2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38551095
2.
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥â¯20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
Euro Surveill
; 28(47)2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37997665
3.
Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.
Euro Surveill
; 21(7): pii=30139, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26924024
4.
I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?
Euro Surveill
; 21(16)2016 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-27124420
5.
Vaccine Effectiveness against GP-Attended Symptomatic COVID-19 and Hybrid Immunity among Adults in Hungary during the 2022-2023 Respiratory Season Dominated by Different SARS-CoV-2 Omicron Subvariants.
Vaccines (Basel)
; 12(5)2024 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38793747
6.
Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.
Vaccine
; 42(16): 3547-3554, 2024 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38704257
7.
Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.
Influenza Other Respir Viruses
; 18(2): e13255, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38403302
8.
Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study.
Influenza Other Respir Viruses
; 18(1): e13243, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38204584
9.
Characteristics of the Third COVID-19 Pandemic Wave with Special Focus on Socioeconomic Inequalities in Morbidity, Mortality and the Uptake of COVID-19 Vaccination in Hungary.
J Pers Med
; 12(3)2022 Mar 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35330387
10.
Unequal burden of COVID-19 in Hungary: a geographical and socioeconomic analysis of the second wave of the pandemic.
BMJ Glob Health
; 6(9)2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34518205
11.
Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016-17 and 2017-18).
Vaccine X
; 3: 100042, 2019 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31660536
12.
2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children.
Influenza Other Respir Viruses
; 12(4): 423-437, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29125681
13.
Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I-MOVE multicentre test-negative case-control study, 2011/2012-2016/2017.
Influenza Other Respir Viruses
; 12(5): 567-581, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29659149
14.
I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe.
PLoS One
; 6(11): e27622, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22110695
Resultados
1 -
14
de 14
1
Próxima >
>>